Arrowhead Rises on Positive Candidate News
Arrowhead Research made waves in the market on Friday afternoon on positive developments surrounding its ARC-HIF2.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 248Short Sellers Become More Selective in Major Pharma
The short interest data have been released for the August 31 settlement date, and for the selected pharmaceutical stocks, short interest is mixed.
Jefferies Starts Coverage on Biotechs: 3 Top Stocks to Buy Now
In a new and very comprehensive report, Jefferies starts coverage on biotechs with some very targeted stock selections.
Short Sellers Increase Bets in Major Biotechs
The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased across the board for this settlement date.
AbbVie Posts Another Win for Humira
ThinkstockAbbVie Inc. (NYSE: ABBV) has continued to push forward over the past year and shares are actually up 7.3% in the past 52-weeks despite the markets pulling back in August. Late Thursday, the company…
La Jolla Gears Up for Secondary Offering
La Jolla Pharmaceuticals has announced the pricing of an underwritten offering of 2.55 million shares of its common stock.
Biogen Follows Gilead With Large Debt Offering
ThinkstockAre biotech companies going to become the next big companies saddled with debt? Most likely not, but two debt offerings will stand out to investors here. The first was a $10 billion multi-part debt…
AnaptysBio Gets Ready for IPO
AnaptysBio Inc. has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Can Akebia Sustain This Move?
Akebia Therapeutics has had a rough time this year, but shares took a sharp left turn in Wednesday's session on news of positive study results.
Penumbra Sets Terms for IPO in New Filing
Penumbra Inc. has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Why Gilead Faces Unenthusiastic Ratings Into Massive Debt Offering
Gilead Sciences is going to raise cash via a huge debt offering. Will this cash be used to fund a large buyout? Will it be used for stock and/or debt buybacks?
Can Tetraphase Survive This Implosion?
When investors see a drop of almost 80% in a share price, the question of long-term viability is almost impossible to ignore.
Is the Huge Jump in Nanosphere Sustainable?
24/7 Wall St. wants to see if Tuesday's move in Nanosphere after an FDA OK is sustainable.
5 Top Biotech Stocks That Ran This Past Week
Over the past week, a few biotech companies made absolutely massive runs. Here is information about some of them, as well as recent trading activity and the consensus price target.
4 New Big FDA Decisions Expected in September
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and added some color.